• Explore /
  • Poster
  • / Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.

Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.

Abstract Video & Slides Poster

Authors

Alexander Drilon

Alexander E. Drilon

Memorial Sloan Kettering Cancer Center, New York, NY

Alexander E. Drilon , David S. Hong , Cornelis Martinus van Tilburg , Francois Doz , Daniel S.W. Tan , Shivaani Kummar , Jessica Jiyeong Lin , Raymond S. McDermott , C. Michel Zwaan , Ricarda Norenberg , Marc Mardoche Fellous , Nicoletta Brega , Rui-hua Xu , Theodore Willis Laetsch , Lin Shen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT02576431, NCT02122913, NCT02637687

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3100)

DOI

10.1200/JCO.2022.40.16_suppl.3100

Abstract #

3100

Poster Bd #

92

Abstract Disclosures

Similar Posters

First Author: David S. Hong

First Author: Leo Mascarenhas

First Author: Maria E. Cabanillas

First Author: Sébastien Perreault